Application of Evolving Evidence in Mantle Cell Lymphoma: Therapeutic Strategies Using BTK Inhibitors

Understand recent data and expert opinions for the optimal use of BTK inhibitors in the treatment of MCL in your clinical practice, featuring an overview of current therapies and optimization of frontline treatment strategies, through an on-demand webcast with accompanying slides and expert-written ClinicalThought commentary.

Share

Program Content

Activities

BTKi for MCL
BTK Inhibitors for Mantle Cell Lymphoma: Overview and Current Treatment Landscape
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2024

Expires: December 04, 2025

Frontline BTKi in MCL
Optimizing Frontline Treatment for MCL: Considerations for BTK Inhibitors in Younger, Fit Patients
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2024

Expires: December 04, 2025

BTKi in MCL Older Patients
Optimizing Frontline Treatment for MCL: Considerations for BTK Inhibitors in Older Patients
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 05, 2024

Expires: December 04, 2025

Faculty

cover img faculity

Brad Kahl, MD

Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St. Louis, Missouri

cover img faculity

John P. Leonard, MD

Senior Associate Dean for Innovation and Initiatives
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine
NewYork-Presbyterian
New York, New York

cover img faculity

Julie M. Vose, MD, MBA

Payne Presidential Chair
Chief, Division of Hematology/Oncology
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca